The application is entitled "A method of providing a cartilage implant with chondrocytes". The approved patent entered into force on the June 14, 2023. The certificate can be seen attached.

Notice of the grant of this patent was received from the EPO and a press release was sent out in April.

This European patent means that Cline's method to develop stem cells into cartilage cells is protected within EPO member states, and thus strengthened the IP protection position of the StemCART end product, which increases value when the project is later sold or out-licensed.

StemCART is an advanced therapy medical product (ATMP) that aims to revolutionize the treatment of cartilage damage for patients worldwide. This is what orthopedic surgeon and key opinion leader Professor Mats Brittberg says about this form of treatment:

"As an orthopedic surgeon but also a researcher, I have spent more than 30 years treating patients with cartilage damage. It is now of great interest to see the new use of stem cells to produce functional cartilage for many patients. This is the next step in cartilage repair." MD, PhD, Professor, Orthopedic surgeon Mats Brittberg.
 

Hear more in a short interview with Mats Brittberg here: https://www.youtube.com/watch?v=3wZ4JXqqPEw

For more information, please contact:

Hanne Evenbratt, Interim CEO and VP - Research & Development

Email: hanne.evenbratt@clinescientific.com

Phone: +46 704 88 79 23